{"id":390456,"date":"2019-03-28T00:00:00","date_gmt":"2019-03-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfon0008-2019-biopharma-myelodysplastic-syndromes-niche-rare-disease-landscape-forecast-us-eu5-2019\/"},"modified":"2026-05-03T23:36:46","modified_gmt":"2026-05-03T23:36:46","slug":"nrlfon0008-2019-biopharma-myelodysplastic-syndromes-niche-rare-disease-landscape-forecast-us-eu5-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfon0008-2019-biopharma-myelodysplastic-syndromes-niche-rare-disease-landscape-forecast-us-eu5-2019\/","title":{"rendered":"Myelodysplastic Syndromes | Niche &#038; Rare Disease Landscape &#038; Forecast | US\/EU5 | 2019"},"content":{"rendered":"<p>Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stemcell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although entrenched options are available to manage anemia in lower-risk (e.g., erythropoiesis-stimulating agents) and higher-risk (e.g., hypomethylating agents) patients, a significant gap in treatment exists for patients who are refractory to the first-line standards of care. The\u00a0MDS\u00a0pipeline is robust and several projected market entrants are poised to penetrate subpopulations of the lower-risk and higher-risk\u00a0MDS\u00a0patients. Although the development of novel agents for higher-risk\u00a0MDS\u00a0patients has been particularly challenging, interviewed experts express enthusiasm for the clinical potential of several agents that are approved or marketed for\u00a0AML, particularly those that target specific genetic populations.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What role(s) will Celgene\/Acceleron\u2019s luspatercept (ACE-536) have in the management of\u00a0MDS\u00a0patients?<\/li>\n<li>What is the commercial outlook for Celgene\u2019s oral azacitidine (CC-486)?<\/li>\n<li>Which emerging therapies are most likely to have an impact on the\u00a0MDS\u00a0therapy market in 2028 (e.g., AbbVie\/Genentech\u2019s Venclexta, Celgene\/Agios Pharmaceuticals\u2019 Idhifa, Jazz Pharmaceuticals\u2019 Vyxeos)? Which early-phase agents intrigue interviewed experts?<\/li>\n<li>How will the size of the\u00a0MDS\u00a0population change through 2028?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Niche &#038; Rare Disease Landscape &#038; Forecast<\/em>\u00a0provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research<\/p>\n","protected":false},"template":"","class_list":["post-390456","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-myelodysplastic-syndromes","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390456\/revisions"}],"predecessor-version":[{"id":576650,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390456\/revisions\/576650"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}